-0.07 | -0.15%
| Price and Volume | |
|---|---|
| Recent Price | 46.80 |
| 52 Week High | 47.80 |
| 52 Week Low | 27.17 |
| Avg. Daily Vol. (Mil) | 1.12 |
| Beta (3 year) | 1.59 |
| Share Related Items | |
| Mkt Cap (Mil) | 3,012.48 |
| Shares Out (Mil) | 64.37 |
| Float (Mil) | 63.85 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.30 |
| Current Ratio | 6.60 |
| LT Debt/ Equity | 0.21 |
| Total Debt / Equity | 0.21 |
| Valuation Ratios | |
| Price Earnings | 42.90 |
| Price/Sales | 6.66 |
| Price/Book | 3.85 |
| Price/Cash Flow | 35.60 |
| Per Share Data | |
| Earnings | 1.09 |
| Sales | 7.02 |
| Book Value | 12.14 |
| Cash Flow | 1.31 |
| Business Summary | |
|---|---|
| Onyx Pharmaceuticals, Inc, is a biopharmaceutical company dedicated to developing innovative therapies that target the molecular mechanisms that cause cancer. | |
| General Information | |
| 249 East Grand Avenue
South San Francisc, CA 94080 |
|
| www.onyx-pharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 420 | |
| CEO: Dr. N. Anthony Coles, M. | |
| Short Interest | |
| Current Month (Mil) | 6.13 |
| Previous Month (Mil) | 6.55 |
| Short Interest Ratio (Days) | 4.40 |
| Management Effectiveness | |
| Return on Equity | 8.80 |
| Return on Assets | 5.00 |
| Return on Investments | 7.30 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | 19.90 |
| Profit Margin | 15.30 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet